According to a meta-analysis of 456 studies, EGFR mutations are found in 32.3% of NSCLC patients, with higher rates in certain countries (38.4% in China), females (43.7% vs. 24.0% in males), non-smokers (49.3% vs. 21.5% in past/current smokers), and patients with adenocarcinoma (38.0% vs. 11.7%; with vs. non-adenocarcinoma) [5]. This evidence concerns the gene EGFR and adenocarcinoma.